Ureteroscopic resection of upper-tract transitional-cell carcinoma.
Technological advances have increased the applicability of endoscopic treatment for upper-tract transitional-cell carcinoma (TCC). Percutaneous and ureteroscopic tumor resection have become reasonable treatment options for patients with anatomically or functionally solitary kidneys, bilateral upper-tract tumors, significant renal insufficiency, or comorbid disease that would preclude standard open surgery. This approach also is being used increasingly on those with a normal contralateral kidney in whom nephroureterectomy and en bloc removal of the ipsilateral ureteral orifice and surrounding bladder cuff is considered the standard therapy. This paper reviews the current role of ureteroscopic management of upper-tract TCC.
Ho
Khai-Linh V
KL
Department of Urology, Mayo Clinic, Rochester, MN 55905, USA.
Chow
George K
GK
D002295:Carcinoma, Transitional Cell / Q000175:diagnosis / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D006801:Humans; D007680:Kidney Neoplasms / Q000175:diagnosis / Q000601:surgery*; D007682:Kidney Pelvis / Q000601:surgery*; D053685:Laser Therapy; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D018666:Ureteroscopy / Q000009:adverse effects / Q000379:methods*